462 related articles for article (PubMed ID: 28185633)
1. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
2. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
[TBL] [Abstract][Full Text] [Related]
3. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma.
Evans JJ; Crist HS; Durvesh S; Bruggeman RD; Goldenberg D
Cancer Biol Ther; 2012 Jul; 13(9):776-81. PubMed ID: 22688732
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.
Balta AZ; Filiz AI; Kurt Y; Sucullu I; Yucel E; Akin ML
Med Oncol; 2012 Jun; 29(2):734-41. PubMed ID: 21547408
[TBL] [Abstract][Full Text] [Related]
6. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.
Wiseman SM; Griffith OL; Deen S; Rajput A; Masoudi H; Gilks B; Goldstein L; Gown A; Jones SJ
Arch Surg; 2007 Aug; 142(8):717-27; discussion 727-9. PubMed ID: 17709725
[TBL] [Abstract][Full Text] [Related]
7. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins.
Mseddi M; Ben Mansour R; Gouiia N; Mnif F; Bousselaa R; Abid M; Boudaouara T; Attia H; Lassoued S
Adv Med Sci; 2017 Mar; 62(1):45-51. PubMed ID: 28187375
[TBL] [Abstract][Full Text] [Related]
9. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
10. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?
Tang J; Gui C; Qiu S; Wang M
World J Surg Oncol; 2018 May; 16(1):100. PubMed ID: 29855303
[TBL] [Abstract][Full Text] [Related]
12. Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis.
Song YS; Jung CK; Jung KC; Park YJ; Won JK
J Korean Med Sci; 2017 Oct; 32(10):1721-1726. PubMed ID: 28875621
[TBL] [Abstract][Full Text] [Related]
13. Histological and immunohistochemical aspects of papillary thyroid cancer.
Radu TG; Mogoantă L; Busuioc CJ; Stănescu C; Grosu F
Rom J Morphol Embryol; 2015; 56(2 Suppl):789-95. PubMed ID: 26429174
[TBL] [Abstract][Full Text] [Related]
14. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of p53 protein expression in papillary thyroid carcinoma.
Morita N; Ikeda Y; Takami H
World J Surg; 2008 Dec; 32(12):2617-22. PubMed ID: 18836853
[TBL] [Abstract][Full Text] [Related]
16. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
17. The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer.
Zhang J; Gill AJ; Issacs JD; Atmore B; Johns A; Delbridge LW; Lai R; McMullen TP
Hum Pathol; 2012 Jul; 43(7):1044-50. PubMed ID: 22204713
[TBL] [Abstract][Full Text] [Related]
18. The Role of Notch1 Signaling in Anaplastic Thyroid Carcinoma.
Kim HJ; Kim MJ; Kim A; Jung CW; Park S; Koh JS; Myung JK
Cancer Res Treat; 2017 Apr; 49(2):509-517. PubMed ID: 27586674
[TBL] [Abstract][Full Text] [Related]
19. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
20. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G
Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
